We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$810M
1-Year Est. Return
30.2%
This Fund
S&P 500
This Quarter
Est. Return
+10.05%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$630M
AUM Growth
+$66.5M
(+12%)
Cap. Flow
+$74.6M
Cap. Flow
% of AUM
11.85%
Top 10 Holdings %
Top 10 Hldgs %
30.71%
Holding
120
New
23
Increased
22
Reduced
38
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$79.9M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$14.1M |
| 3 |
Merck
MRK
|
+$12.3M |
| 4 |
AGN
Allergan plc
AGN
|
+$6.72M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$6.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$20M |
| 2 |
Pfizer
PFE
|
+$13.2M |
| 3 |
Medtronic
MDT
|
+$11M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$8.02M |
| 5 |
CPHD
Cepheid Inc
CPHD
|
+$8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.01% |
| 2 | Financials | 0.83% |
| 3 | Technology | 0.09% |
| 4 | Energy | 0.06% |
| 5 | Industrials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
JPMorgan Chase
JPM
$950B
| $179K | 0.03% |
+2,688
| New | +$175K |
|
102
Ford
F
$55.7B
| $176K | 0.03% |
+14,611
| New | +$184K |
|
|
MTEM
103
DELISTED
Molecular Templates, Inc.
MTEM
| $137K | 0.02% |
1,221
| – | – |
|
104
Abbott
ABT
$187B
| – | – |
-84,100
| Closed | -$3.31M |
|
105
Becton Dickinson
BDX
$48.2B
| – | – |
-15,375
| Closed | -$2.54M |
|
106
Community Health Systems
CYH
$423M
| – | – |
-175,000
| Closed | -$2.11M |
|
107
Elevance Health
ELV
$85.5B
| – | – |
-40,000
| Closed | -$5.25M |
|
|
108
Gilead Sciences
GILD
$165B
| – | – |
-240,000
| Closed | -$20M |
|
109
LivaNova
LIVN
$4.2B
| – | – |
-70,000
| Closed | -$3.52M |
|
|
110
Medtronic
MDT
$112B
| – | – |
-127,000
| Closed | -$11M |
|
|
111
Pfizer
PFE
$153B
| – | – |
-395,250
| Closed | -$13.2M |
|
112
Ultragenyx Pharmaceutical
RARE
$2.55B
| – | – |
-10,000
| Closed | -$489K |
|
|
CERN
113
DELISTED
Cerner Corp
CERN
| – | – |
-81,000
| Closed | -$4.75M |
|
|
QHC
114
DELISTED
Quorum Health Corporation
QHC
| – | – |
-56,250
| Closed | -$602K |
|
|
CPHD
115
DELISTED
Cepheid Inc
CPHD
| – | – |
-260,000
| Closed | -$8M |
|
|
MDVN
116
DELISTED
MEDIVATION, INC.
MDVN
| – | – |
-80,000
| Closed | -$4.82M |
|
Similar funds
PS
ACM
AR
KCP
BCM
RIM
GCM
CL
Rhenman & Partners Asset Management's Q3 2016 Portfolio in Review
As of Q3 2016, Rhenman & Partners Asset Management held 120 positions worth $630M, up 12% from $563M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Rhenman & Partners Asset Management deployed $74.6M of net new capital in Q3 2016, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Shire pic: 409,858 shares worth $26.6M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.02M trimmed.
- Rhenman & Partners Asset Management's largest Q3 2016 buy was Shire pic: 409,858 shares worth $26.6M.
- Rhenman & Partners Asset Management added most to Allergan plc in Q3 2016, an estimated $6.72M increase.
- Rhenman & Partners Asset Management's biggest Q3 2016 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.02M.
- Rhenman & Partners Asset Management fully exited Gilead Sciences in Q3 2016, selling an estimated $20M.
- Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $630M portfolio in Q3 2016.
- Rhenman & Partners Asset Management opened 23 new positions and closed 13 in Q3 2016.
- Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $630M.
Based on Rhenman & Partners Asset Management's 13F filing for Q3 2016, filed 8 Nov 2016.